Table A2.
Additional treatment after discontinuation of LEN.
| LEN Combined with TIT | LEN Monotherapy | p | |
|---|---|---|---|
| n | 17 | 19 | |
| Additional treatment | 64.7% (11/17) | 73.6% (14/19) | 0.559 |
| Atez/Bev | 17.7% (3/17) | 21.0% (4/19) | |
| RAM | 11.8% (2/17) | 0.0% (0/19) | |
| SORA | 11.8% (2/17) | 21.0% (4/19) | |
| REGO | 0.0% (0/19) | 5.3% (1/19) | |
| TACE | 23.5% (4/17) | 10.7% (2/19) | |
| HAIC | 0.0% (0/17) | 21.0% (4/19) | |
| Best supportive care | 35.2% (6/17) | 21.0% (4/19) |
Abbreviations: LEN, lenvatinib; TIT; Transcatheter intraarterial therapies; Atez/Bev, Atezolizumab and Bevacizumab; RAM, ramucirumab; SORA, Sorafenib; REGO, Regorafenib; TACE; transcatheter arterial chemoembolization, HAIC; hepatic arterial infusion chemotherapy.